Antiplatelet drugs are often discontinued early after ischaemic stroke, either because of poor compliance, complications or withdrawal of care. It is unclear whether this places patients at increased risk of recurrence. We explored the association between cardiovascular event rate and persistence with prescribed antiplatelet drugs.
Introduction
There is a risk of recurrence following acute ischaemic stroke [7] . Antiplatelet therapy is given to reduce this risk and the risk of other vascular outcomes [8, 9] . National Institute for Health and Clinical Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) guidelines recommend that antiplatelet therapy must be started early and continued indefinitely for long-term secondary stroke prevention [9, 10] . In the UK, guidelines favour aspirin therapy for 2-weeks followed by clopidogrel or the combination of low-dose aspirin and dipyridamole.
Persistence with antiplatelet regimens is variable after stroke. Rates of aspirin discontinuation of <10% to almost 50% are reported [11, 12] . At 1 year, as many as 50% of patients who were prescribed aspirin or clopidogrel either discontinued or failed to adhere to their regimen [13] [14] [15] . This may be for several reasons, including patient noncompliance, bleeding complications, financial pressures, or physician-directed withdrawal due to withdrawal of care, intercurrent illness or planned procedures [16] . Interrupting or stopping antiplatelet therapy may increase the risk of cardiovascular events in patients with a history of cardiovascular or cerebrovascular disease [17, 18] . One study found that among the 2197 cases of ischaemic stroke, 5.2% cases occurred within 60 days after antithrombotic withdrawal [16] . In this study, stroke events were clustered mostly in the first 7 days after stopping medication. Antithrombotic medication was stopped for various reasons including being stopped by physicians for procedures, patient compliance, bleeding complications and cost. In another study by García Rodríguez et al. [17] , among 673 patients who had been diagnosed with ischaemic stroke or transient ischaemic attack (TIA), 71.3% patients were taking aspirin on the day of event and 10% discontinued aspirin within 31-180 days before the event. By contrast, a recent prospective observational study found that interruption of antiplatelet therapy due to surgical necessity was not associated with increased risk of cardiovascular events [19] .
Data to demonstrate the impact of stopping antiplatelet therapy early after ischaemic stroke, where recurrence rate is highest, are lacking. We aimed to explore the rate of antiplatelet cessation and interruption in a sample of patients with recent ischaemic stroke and assess the risk of cardiovascular events associated with cessation and interruption of antiplatelet drugs.
Methods

Study design
We used a matched case-control study design to examine association between antiplatelet exposure and risk of a cardiovascular event. We used individual matching to identify up to four controls for each case, matched by age ± 10 years and sex. We followed the STROBE guidance in reporting this case-control study [20] .
Data sources
We used data from the Virtual International Stroke Trials Archive (VISTA) [21] . VISTA is a collaborative registry that collates and provides access to anonymised data from completed clinical trials. VISTA data are stored at the Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK. VISTA contains patients' demographic data such as age, sex and ethnicity; smoking history; and comorbid conditions as well as details on the index stroke and functional outcome measures. Adverse event (AE) data, laboratory measurements and prescribed medications are available from certain trials. All trials lodged in VISTA already have local institutional review board approved procedures in accordance with the Declaration of Helsinki. Thus, our analysis does not require a new study approval. Nevertheless, access to data is subject to approval by the steering committee.
Study cohort
All acute ischaemic stroke patients in the VISTA who took antiplatelet therapy and had complete information on initiation day of antiplatelet therapy were identified. Patients with concurrent use of vitamin K antagonist such as warfarin were excluded as it may influence clinical [22] and safety [23] outcomes in acute ischaemic stroke patients. Patients who had a cardiovascular event within the first 2 days after ischaemic stroke were excluded as the event might not be associated to antiplatelet but due to the specific pattern of ischaemic changes after acute stroke [24] .
Cases were defined as patients who had at least one cardiovascular event in the first 90 days after acute ischaemic stroke. A cardiovascular event was defined as a acute coronary syndrome (ACS), recurrent ischaemic stroke or TIA. The event was identified from AE and serious AE reports datasets using these key terms: (a) for ACS -unstable angina, acute coronary syndrome or myocardial infarction; (b) for recurrent ischaemic stroke -stroke, cerebral infarction or cerebrovascular accident; and (c) TIA. Controls were identified from the same source to minimize the potential of bias [25] . Controls were defined as patients who had no cardiovascular event within 90 days after acute ischaemic Figure 1 Flowchart of patients' selection Stopped and interrupted AP stroke. The flowchart of patient selection is shown in Figure 1 . The sample size was determined by the number of cases available in the study cohort.
Antiplatelet drug exposure
The information on antiplatelet drugs was obtained from the current medication dataset in VISTA. Data on start and stop dates of antiplatelet drugs were available on certain trials that had monitored start and stop dates for all medications. Antiplatelet drugs were identified using the World Health Organization's Anatomical Therapeutic Chemical classifications, i.e. antiplatelet with Anatomical Therapeutic Chemical code: B01AC. The antiplatelet exposure period for each patient began after the diagnosis of acute ischaemic stroke and ended at the index date. The index date was the date of the first cardiovascular event recorded after antiplatelet exposure in cases. In controls it was the same date as the matched case [26, 27] . Exposure to antiplatelet drugs prior to the index date was classified as persistent use, early cessation, interruption, or stopped ( Figure 2 ). Persistent use was defined as taking antiplatelet therapy up to, or within 3 days of the index date. Patients who switching to another antiplatelet therapy were considered as continuing antiplatelet treatment. Early cessation was defined as patient who took antiplatelet therapy <3 days poststroke or prior to the index date. Interruption was defined as taking antiplatelet therapy up to, or within 3 days of the index date, but with 3 days or more interrupted use. Stopped was defined as stopping antiplatelet therapy at least 5 days before the index date.
Bleeding events
Bleeding events occurring during the study period were divided into two categories (intracerebral haemorrhage and extracranial haemorrhage). Intracerebral haemorrhage did not include haemorrhagic transformation 1 and 2 of cerebral infarction, which were not counted. Extracranial haemorrhage was defined as all other types of bleeding and was split into gastrointestinal and nongastrointestinal bleeding. This information was extracted from AE and serious AE datasets in VISTA.
Statistical analysis
Descriptive statistics were recorded for cases and controls and according to the three types of antiplatelet exposures. The Chi-square test was used to compare baseline characteristics between cases and controls. Comparison between antiplatelet exposures group were conducted using the Kruskal-Wallis test or the chi-square test depending on the distribution and nature of the data. Categorical variables were summarized using frequencies and proportions and continuous variables as mean (standard deviation) or median (interquartile range).
We used conditional logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI) for risk of cardiovascular event associated with exposures of antiplatelet before the index date. We first conducted univariable analyses. In multivariable analysis, we first included all significant variables (first model). We then consecutively dropped the least significant variable until all included variables were significant at P < 0.05 (final model). A P < 0.05 was considered significant. Point estimates and 95% CI are presented for all results. We used a complete-case approach to analysis so there was no imputation of missing data. All analyses were performed using IBM SPSS Statistics version 21.0 [28] .
A posthoc power analysis to determine the power of the study and the sample size needed to detect a desired degree of statistical power was performed using PS (version 3.0 2009) to address the likelihood of type II error.
Results
Study population
Complete data were available for analysis of antiplatelet exposure in 4050 patients. Of these, 194 patients had at least one cardiovascular event (126 ischaemic stroke, 45 ACS and 23 TIA) within 90 days following acute ischaemic stroke. These cases were matched to 776 controls. Baseline characteristics of patients with cardiovascular event and Patients who interrupted/stopped their antiplatelet therapy had higher baseline NIHSS and were more likely to have previous ischaemic heart disease and stroke (Table 2) than persistent users. Aspirin was the most common antiplatelet prescribed followed by clopidogrel for both cases and controls (Table 3 ). More than two thirds of persistent users, early cessation and interrupted/stopped users were exposed to aspirin and followed by clopidogrel ( Table 4 ). The occurrence of bleeding events was highest in interrupted/stopped users (10.3%) followed by early cessation users (7.6%; Table 5 ).
Antiplatelet exposure and cardiovascular event.
There was no significant difference in cardiovascular event rate in early cessation and interrupted/stopped users compared to persistent users on univariable analysis (OR 1.07, 95% CI 0.67, 1.71; P = 0.784 and OR 0.67, 95% CI 0.34, 1.36; P = 0.269, respectively; Table 6 ). Results were similar following adjustment (adjusted OR 1.04, 95% CI 0.62, 1.74; P = 0.876 and OR 0.70; 95% CI 0.33, 1.48; P = 0.352 respectively) ( Table 7) .
Discussion
We performed a nested case-control study to explore the relationship between stopping or interrupting antiplatelet drugs and cardiovascular risk in patients with recent ischaemic stroke. We found no evidence for an increased risk of cardiovascular among patients who stopped or had interrupted use of antiplatelets.
We found that the rates of early cessation of antiplatelet therapy were higher in our study compared to others [29, 30] . We defined early cessation as taking an antiplatelet for fewer than 3 days post-stroke or before a cardiovascular event. We used this definition because most patients took aspirin and fewer than 3 days of aspirin use is unlikely to lead to full inhibition of platelets [31] .
Withdrawal of antiplatelets is associated with an increase in thromboxane A2 activity [32] which could increase the risk of ischaemic stroke [16, 17, 33] . These studies found that discontinuation of antiplatelet therapy within 1-6 months is associated with increased risk of ischaemic stroke or TIA. We did not see an increase and several factors could explain the difference between our findings and previous studies. First, our sample size was small compared to the studies by García Rodríguez et al. [17] [34] and found no increased risk. This suggests the risk of stopping or interrupting antiplatelet drugs may be acceptable in the short term and we wished to assess whether this was the case after stroke. After stroke, there are several reasons why clinicians may be faced with decisions regarding continuing or stopping antiplatelets. These include bleeding complications and other adverse events such as worsening stroke symptoms or changes in haematological measures. At present, few data exist to inform these decisions in terms of risk of recurrence following cessation. Our study should reassure that, if clinically indicated, the short-term risk of stopping antiplatelets does not appear to be significantly increased.
In the present study, comorbidity was more common in cases and stroke severity was higher in patients who were interrupted or stopped users. We also found stroke severity, age, hypertension, diabetes and quality of life were related to the pattern of antiplatelet use. Patients with higher stroke severity, previous stroke and lower life quality were more likely to stop. Although we cannot be sure, this is likely to reflect the underlying reasons for stopping treatment, such Table 3 Characteristics of antiplatelet regimen prescribed 
Table 4
Frequency of antiplatelet regimen according to types of antiplatelet exposure Stopped and interrupted AP as change in clinical condition or withdrawal of care. Early cessation users had a higher rate of atrial fibrillation which may be explained by decisions to start anticoagulation therapy. By contrast, interrupted/stopped users had a higher rate of bleeding suggesting; this also influenced the reason to interrupt or stop antiplatelet therapy.
Strengths and limitations
Despite their known problems of bias and confounding, casecontrol designs are efficient in examining the association between outcomes and exposures. VISTA database sample provided data that were prospectively collected during clinical trials in patients with confirmed ischaemic stroke. We minimized selection bias by including all cases of cardiovascular event within the selected time period (3-90 days) and matched controls, free of the outcome of interest and independent of the exposure of interest. Matching for age and sex increased the precision of our results compared with those of previous unmatched casecontrol studies. Information on exposures was recorded in the database, eliminating recall bias. An important limitation of this study is the lack of information on the underlying reasons for interruption/ stopping of antiplatelets. This limits the generalizability of our findings to clinical practice. Generalizability is further limited by the fact that data come from a clinical trial registry and because most patients took aspirin and few received the combination of aspirin-dipyridamole or clopidogrel as recommended in national and international guidelines. The main limitation is study power. Although there is a large number of cases and controls, the number of patients with the different antiplatelet exposures was limited. Post hoc analysis revealed that this study, at α < 0.05, with 194 cases and matched with four controls has insufficient power (0.239). Thus, to obtain 80% power, with the level of α 0.05, 801 cases with four matched controls per case are needed. 
Conclusion
We found no significant association between interrupted or stopped use of antiplatelets and risk of cardiovascular events. This might reassure clinicians who need to stop antiplatelets for clinical reasons. However, our study had limited power and a clinically important risk cannot be excluded. Further research is needed.
